New cocktail targets untreatable liver cancer
NCT ID NCT04380545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15 patients and primarily look at side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (immunotherapy), fluorouracil (chemotherapy), and interferon alpha 2b (immune stimulant)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with fibrolamellar liver cancer that cannot be surgically removed.
- What could go wrong
- This is a very early, small trial (15 people) focused on safety and response. The combination may cause significant side effects and may not shrink tumors in most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- New drug zanzalintinib tested for advanced liver cancer
- Home monitoring may keep cancer patients out of the ER
- Experimental combo aims to rally immune system against tough liver cancer
- Liver cancer drug trial halted after just 3 patients
- New combo therapy aims to shrink untreatable liver tumors